The Bulls Are Using Margin Again. Here’s How Well That Has Ended in the Past.
Let’s look at today’s indicators with an eye to the past to get a look at a possible future scenario.
These Biopharma Names Don’t Have the Flash of SpaceX, but They’re Reliable
Here are four biotech plays that should stand up if the market starts to break down.
While Everyone Was Selling, I Initiated a New Position in This Mid-Cap Biotech
I made exactly one trade Friday — and I went to Denmark to do it.